New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Strive Health Raises $140 Million Led by Alphabet’s CapitalG to Tackle $410 Billion of Unmanaged Kidney Disease Spend
-
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
Lumos Pharma to Participate in March 2021 Investor Conferences
-
CIT GAP Funds Makes Follow-On Investment in RoundlyX to Help Users Better Manage Digital Asset Portfolios
-
Form SC 13D/A TREVENA INC Filed by: New Enterprise Associates 12, Limited Partnership
-
Form SC 13D/A Allakos Inc. Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A DZS INC. Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Form SC 13D/A Tracon Pharmaceuticals, Filed by: New Enterprise Associates 14, L.P.
-
Form SC 13D/A Viracta Therapeutics, Filed by: New Enterprise Associates 12, Limited Partnership
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
-
Quantum Computing Company IonQ to Merge with SPAC dMY Technology Group, Inc. III (DMYI)
-
IonQ To Become The First Publicly Traded Pure-Play Quantum Computing Company
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
-
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
-
Résultats annuels 2020 : Avancées majeures dans la NASH et visibilité financière significativement étendue suite au succès de l’introduction en bourse aux États Unis
-
Lumos Pharma (LUMO) Says Data Supporting Use of Predictive Enrichment Markers for its LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma’s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society
-
OmniSci Launches Free Edition of Platform to Democratize the Power of Accelerated Analytics
-
Humana and the University of Houston Announce New Value-based Care Specialization Program
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
-
Nuvolo Raises $31M Series C Funding to Accelerate Global Expansion and IWMS Platform Evolution
-
Satsuma Pharmaceuticals Inc. (STSA) Announces $80 Million Private Placement Financing
-
Satsuma Pharmaceuticals Announces $80 Million Private Placement Financing
-
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
-
Form SC 13D Metromile, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Woebot Health Forms Clinical Diversity Advisory Board
-
SoftBank-backed robotics firm Berkshire Grey to go public via $2.7 billion SPAC deal
-
AI Developer Berkshire Grey Announces Business Combination with SPAC Revolution Acceleration Acquisition Corp (RAAC)
-
Berkshire Grey, a Leader in AI-Enabled Robotics and Automation Solutions, Announces Business Combination with Revolution Acceleration Acquisition Corp
-
Lightbank Closes New Venture Capital Fund, Raising $180 Million
-
Topia Survey: 28% of Employees Worked Outside Their Home State or Country During the Pandemic, But Only 1/3 Reported It to HR
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
-
Winner of the AIM-HI Accelerator Fund's Inaugural Women's Venture Competition Announced
-
Appili Therapeutics to Host Series of Virtual Fireside Chats; First Event to Feature Dr. Scott Gottlieb to Discuss Critical Need for More Options to Combat COVID-19
-
Sentry Raises $60 Million in Series D Funding at $1 Billion Valuation
-
Avoro Ventures Adds Sara Nayeem, MD, as a Partner
-
Cartus Joins Forces with Topia to Offer First-of-its-Kind Distributed Workforce Compliance Solution
-
CIT GAP Funds Invests in Sweetie Boy Delivers to Simplify Transportation Needs for Automotive Dealers
-
Lumos Pharma Announces Changes to its Board of Directors
-
Lumos Pharma Announces Changes to its Board of Directors
-
Form SC 13G Annexon, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13G Inozyme Pharma, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13G/A Surface Oncology, Inc. Filed by: New Enterprise Associates 14, L.P.

